**6. References**


Enkorten – A Potential Drug for the Treatment of Rheumatoid Arthritis 169

Ceriani, G., Diaz, J., Murphree, S., Catania, A., Lipton, J.M. (1994). The neuropeptide alpha-

Cooper, A., Robinson, S.J., Pickard, C., Jackson, C.L., Friedmann, P.S., Healy, E. (2005). -

EMA: European Medicines Agency Questions and Answers on the withdrawal of the Note

Getting, S.J. (2006). Targeting melanocortin receptors as potential novel therapeutics.

Gupta, A.K., Diaz, R.A., Higham, S., Kone, B.C. (2000). -MSH inhibits induction of

Hassoun, H.T., Zou, L., Moore, F.A., Kozar, R.A., Weisbrodt, N.W., Kone, B.C. (2002).

reperfusion injury. *Am J Physiol Gastrointest Liver Physiol* 282: G1059–G1068. Hill, R.P., MacNeil, S., Haycock, J.W. (2006). Melanocyte stimulating hormone peptides inhibit TNF-a signaling in human dermal fibroblast cells. *Peptides* 27: 421–430. ICH: International Conference on Harmonisation. Guidance on Nonclinical Safety Studies

Jankovic, B., Maric, D. Enkephalins as regulators of inflammatory immune reactions. In:

Jankovic, B.D. (1991). Enkephalins and immune inflammatory reactions. *Estrallo da Acta* 

Jankovic, B.D., Maric, D. (1987). Enkephalins and anaphylactic shock: Modulation and

Jung, E.J., Han, D.J., Chang, S.H., Lim, D.G., Wee, Y.M., Kim, J.H., Koo, S.K., Choi, M., Kim,

Konjevoda, P., Štambuk, N., Aralica, G., Pokrič, B. (2001). Cytoprotective effects of met-

Konjevoda, P., Štambuk, N., Vikić-Topić, D., Boban-Blagajić, A., Vikić-Topić, S., Mrljak, V.,

alcohol induced gastric lesions. *Croatica Chemica Acta* 73 (4): 1111-1121. Kusturica, J., Mulabegović, N., Kapic, E., Krehić, J., Mandal, S. et Bečić, F. (2009).

prevention of shock in the rat. *Immmunol Lett* 15: 153.

Pharmacokinetics of Encorten. *HealthMed* 3 (2):159-165.

Use. 2010: http://www.ema.europa.eu (accessed November 2, 2010). Gad, C.S. and Chengelis P.C. Acute Toxicology Testing. Second edition. Academic Press,

*Neuroimmunomodulation* 1: 28-32

*Immunol* 175: 4806–4813.

*Pharmacol Ther* 111 (1): 1-15.

*Kidney Int* 57: 2239–2248.

Pharmaceuticals M3(R2), 2009.

Verlag Berlin Heidelberg, 1994

*Neurologica* 13 (XLVI) N0 5

*Transplant Proc* 39: 1604–1606.

*Physiology* 95: 277-281.

USA, 1998.

melanocyte-stimulating hormone inhibits experimental arthritis in rats.

Melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. *J* 

for guidance on single dose toxicity. Committee for Medicinal Products for Human

C/EBPβ-DNA binding activity and NOS2 gene transcription in macrophages.

Alpha-melanocyte-stimulating hormone protects against mesenteric ischemia-

for the Conduct of the Human Clinical Trials and Marketing Authorization for

Neuropeptides and Immunoregulation. Scharrer et al. Eds. pp: 76-100, Springer-

S.C. (2007). Protective effect of -melanocyte-stimulating hormone on pancreas islet cell against peripheral blood mononuclear cell-mediated cytotoxicity in vitro.

encephalin and -MSH on ethanol induced gastric lesions in rats. *Journal of* 

Pavan, J., Ramadan, P., Bididn, Z. (2000). Protective effects of Met-encephalin on


Bečić, F., Mulabegović, N., Kapić, E., Rakanović-Todić, M., Kusturica, J., Ašćerić, M., Loga-

Bhardwaj, R.S., Becher, E., Mahnke, K., Hartmeyer, M., Schwarz, T., Scholzen, T. et al. (1997).

Böhm, M., Eickelmann, M., Li, Z., Schneider, S.W., Oji, V., Diederichs, S., Barsh, G.S., Vogt,

Brunton, L.L., Parker, L.K. (eds.) Goodman and Gilmans Manual of Pharmacology and Therapeutics, 1st edition. McGraw-Hill Companies, 2008; p 349-382, 1023-1036. Brzoska, T., Luger, T.A., Maaser, C., Abels, C., Böhm, M. (2008). -Melanocyte-Stimulating

Cabot, P.J., Carter, L., Schäfer, M., Stein, C. (2001). Methionine-enkephalin-and Dynorphin

Cannon, J.G., Tatro, J.B., Reichlin, S., Dinarello, C.A. (1986). -Melanocyte stimulating

Capsoni, F., Ongari, A., Colombo, G., Turcatti, F., Catania, A. (2007). The synthetic

Caruso, C., Durand, D., Schiöth, H.B., Rey, R., Seilicovich, A., Lasaga, M. Activation of

Catania, A., Airaghi, L., Colombo, G. and Lipton, M.J. (2000). - Melanocyte-stimulating hormone in Normal Human Physioligy and Disease States. *TEM* 11 (8): 304-308. Catania, A., Cutuli, M., Garofalo, L., Carlin, A., Airaghi, L., Barcellini, W. and Lipton, J.M.

Catania, A., Delgado, R., Airaghi, L., Cutuli, M., Garofalo, L., Carlin, A., Demitri, M.T.,

Catania, A., Gatti, S., Colombo, G., Lipton, J.M. (2004). Targeting melanocortin receptors as a

Actions. *Annals of the New York Academy of Sciences* 885:183-187.

novel strategy to control inflammation. *Pharmacol Rev* 56: 1–29.

Mediated Inflammatory Diseases. *Endocrine Reviews* 29 (5): 581-602.

Amsterdam, *Medimond S.r.l:* 221-226.

3384.

4635–4646.

*Immunol* 137: 2232–2236

*Endocrinology* 148: 4918–4926.

231.

neutrophils. *Peptides* 28(10): 2016-2022.

Zec S. (2007). Evaluation of toxicity of combination met-encephaline and alphamelanocyte-stimulating hormone with the aim to calculate clinical studies. 8th Congress of the European Association for Clinical Pharmacology and Therapeutics.

Evidence for the differential expression of the functional alpha melanocyte stimulating hormone receptor MC-1 on human monocytes. *J Immunol* 158: 3378-

A., Stieler, K., Blume-Peytavi, U., Luger, T.A. (2005). Detection of functionally active melanocortin receptors and evidence for an immunoregulatory activity of melanocyte-stimulating hormone in human dermal papilla cells. *Endocrinology* 146:

Hormone and Related Tripeptides: Biochemistry, Anti-inflammatory and Protective Effects *in Vitro* and *in Vivo*, and Future Perspectives for the Treatment of Immune-

A-release from immune cells and control of inflammatory pain. *Pain* 93(3): 207-212.

hormone inhibits immunostimulatory and inflammatory actions of interleukin 1. *J* 

melanocortin (CKPV)(2) exerts broad anti-inflammatory effects in human

melanocortin 4 receptors reduces the inflammatory response and prevents apoptosis induced by lipopolysaccharide and interferon- in astrocytes.

(2000a). The neuropeptide alpha- MSH in host defence. *Amm NY Acad Sci* 917: 227-

Lipton, J.M. (1999). Alfa-MSH in Systemic Inflammation: Central and Peripheral


Enkorten – A Potential Drug for the Treatment of Rheumatoid Arthritis 171

Rakanović-Todić, M., Mulabegović, N., Becic, F., Mijanovic, M., Loga-Zec, S., Kusturica, J.,

Combination of Tridecactide and Met-Enkephalin. *Folia Medica* 46(1):13-22. Rang, H.P., Dale, M.M., Ritter, J.M., Moore, P.K. (2005). Pharmacology. First edition in the Serb language. Edited by Z. Todorović. Belgrade. Data status, 747-752. Rang, H.P., Dale, M.M., Ritter, J.M., Moore, P.K. (2005). Pharmacology. First edition in the Serb language. Edited by Z. Todorović. Belgrade. Data status, 217-242. Rittner, H.L., Brack, A., Stein, C. (2003). Pro-algesic versus analgesic actions of immune cells.

Rittner, H.L., Labuz, D., Schaefer, M., Mousa, S.A., Schulz, S., Schafer, M., Stein, C., Brack, A.

Sarkar, A., Sreenivasan, Y., Manna, S.K. (2003). -Melanocyte-stimulating hormone induces cell death in mast cells: involvement of NF-kB. *FEBS Lett* 549: 87–93. Scholzen, T.E., Sunderkötter, C., Kalden, D.H., Brzoska, T., Fastrich, M., Fisbeck, T.,

endothelial cell adhesion molecule expression. *Endocrinology* 144: 360–370. Štambuk, N., Breljak, D., Križanac-Begenez, Lj. and Boranić, M. (1996). A model of met-

Štambuk, N., Brnar, V., Štambuk, V., Svoboda-Beusan, I., Rabatić, S., Mazuran, R. et al.

Star, A.R., Rajora, N., Huang, J., Stock, C.R., Catania, A., Lipton, M.J. (1995). Evidence of

Stein, C., Machelska, H., Schäfer, M. (2001). Peripheral analgesic and anti-inflammatory

Todić, M., Mulabegović, N., Becić, F., Kusturica, J. (2007). Subacute toxicity study of

Tsatmali, M., Graham, A., Szatkowski, D., Ancans, J., Manning, P., McNeil, C.J., Graham

Veljić, J., Marić, D., Janković, B.D. (1991). Changes of experimental allergic

Vujić-Redžić, V., Dimitrijević, M., Stanojević, S., Kovačević-Jovanović, V., Miletić, T.,

Reactions and Behavior in the Rat. *NeuroImmunoModulation* 8: 70-77. Wybran, J., Appelboom, T., Famaey, J.P., Govaerts, A. (1985). Suggestive evidence for

lymphocytes. *The Journal of Head and Face Pain* 25: 259.

oxide production in melanocytes. *J Invest Dermatol* 114: 520–526.

(2006). Pain control by CXCE2 ligands through Ca2+ regulated release of opioid

Armstrong, C.A., Ansel, J.C., Luger, T.A. (2003). -Melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating

enkephalin induced alterations of the bone marrow cell proliferation. *Periodicum* 

(1997). Peptide M (Lupex(R)) immunotherapy in multiple sclerosis, optic neuritis

autocrine modulation of macrophage nitric oxide synthase by melanocyte-

combination of adrenocorticotropine 1-13 and met-enkephalin. *Med Arh*. 61( 4):199-

A.M., Thody, A.J. (2000). -Melanocyte-stimulating hormone modulates nitric

encephalomyelitis by methionine-enkephalin injected into lateral ventricles of the

Radulović, J. (2000). Peripheral Effects of Methionine-Enkephalin on Inflammatory

receptors for morphine and methionine- enkephalin on normal human blood T

*Curr Opin Anaesthesiol* 16: 527-533.

*Biologorum* 96 (1): 115-118.

202.

peptides from polyprpho nuclear cells. *FASEB J*

and uveitis. *Journal of Etymology* 5(8-9): 448-464.

effects of opioids. *J Rheumatol 6*0: 416-424.

rat brain. *Int J Neurosci* 59(1-3): 81-89.

stimulating hormone. *Proc Natl Acad Sci USA* 92: 8016-8020.

Burnazović-Ristić, L., Kulo, A., Kapić, E. (2011). Acute Toxicity Study of


Lipton, J.M., Catania, A., Ichiyama, T. (2000). Marshaling the anti-inflammatory influence of

Lipton, M.J. and Catania, A. (1997). Anti-inflamatory actions of the neuroimunomodulator

Luger, T.A. et al. (2003). New insights into the functions of alpha-MSH and related peptides in the immune system. *Annals of the New York Academy of Sciences* 994: 133-140. Luger, T.A., Brzoska, T. (2007). -MSH related peptides: a new class of anti-inflammatory

Mandrika, I., Muceniece, R., Wikberg, J.E. (2001). Effects of melanocortin peptides on

Manna, S.K., Sarkar, A., Sreenivasan, Y. (2006). -Melanocyte-stimulating hormone down-

Menzebach, A., Hirsch, J., Hempelmann, G., Welters, D. (2003). Effects of endogenous and

Mousa, S.A., Zhang, Q., Sitte, N., Ji, R., Stein, C. (2001). Beta-Endorphin-containing memory-

Mulabegović, N., Rakanović-Todić, M. (2008). Pharmacodynamic Properties of Combination of Met-enkephalin and Alpha 1-13 Corticotropine. *Medicinski Arhiv* 62(1):41-4. Namba, K., Kitaichi, N., Nishida, T., Taylor, A.W. (2002). Induction of regulatory T cells by

Nicolaou, A., Estdale, S.E., Tsatmali, M., Herrero, D.P., Thody, A.J. (2004). Prostaglandin

Oktar, B.K., Yuksel, M., Alican, I. (2004). The role of cyclooxygenase inhibition in the effect

Plotnikoff, N.P., Wybran, J. (1991). Methionine enkephalin: activation of NK-K-LAK cells in AIDS patients. *Int Conf AIDS.* Jun 16-21; 7: 216 (abstract no. W.B.2139). Puehler, W., Rittner, H.L., Mousa, S.A., Brack, A., Krause, H., Stein, C. (2006). Interleukin-1

Rajora, N., Boccoli, G., Burns, D., Sharma, S., Catania, A.P., Lipton, J.M. (1997). -MSH

peritoneal neutrophils. *Prostaglandins Leukot Essent Fatty Acids* 71: 1–5. Plotnikoff, N., Faith, R.E., Murgo, A.J., Herberman, R.B., Good, R.A. (1997). Short analytical

ganglia in response to peripheral inflammation. *Neuroscience* 16.

inflammation. *The Journal of Neuroscience* 17 (6): 2181-2186.

transforming growth factor-beta2. *J leukoc Biol* 72; 946-952.

and immunomodulating drugs. *Annals of the Rheumatic Diseases* 66 (Suppl 3): iii52-

lipopolysaccharide/interferon--induced NF-B DNA binding and nitric oxide production in macrophage-like RAW 264.7 cells: evidence for dual mechanisms of

regulates CXC receptors through activation of neutrophil elastase. *Eur J Immunol*

synthetic opioid peptides on neutrophil function *in vitro. British Journal of* 

cells and mu-opioid receptors undergo transport to peripheral inflamed tissue. *J* 

the immunomodulating cytokines alpha-melanocyte-stimulating hormone and

production by melanocytic cells and the effect of -melanocyte stimulating

of -melanocyte-stimulating hormone on reactive oxygen species production by rat

review: Methionine enkefalin: A new cytokine-human studies. *Clinical Immunology* 

beta contributes to the upregulation kappa opioid receptor mrna in dorsal root

modulates local and circulating tumor necrosis factor- in experimental brain

the neuroimmunomodulator -MSH. *News Physiol Sci* 15: 192–195.


action. *Biochem Pharmacol* 61: 613–621.

iii55.

36: 754–769.

*Anaesthesia* 91(4): 546-550.

*Neuroimmunol* 115: 71-78.

hormone. *FEBS Lett* 570: 223–226.

*and Immunopathology* 82(2): 99-101.


**9** 

*Japan* 

**Role of Adrenomedullin in Patients with** 

*Division of Orthopaedic Surgery, Department of Medicine of Sensory and* 

The mechanism of arthritis including rheumatoid arthritis (RA) has not been clarified enough in terms of its molecular biology. However, owing to advances in techniques to produce monoclonal antibodies and genetic engineering techniques to produce recombinant proteins, targeted therapies have progressed. Tumor necrosis factor-alpha (TNF-), interleukin-1 (IL-1), interleukin-6 (IL-6), and T-cells (CD28) are representative targets, and therapies targeting them have produced epoch-making results in the treatment of RA. In this text, we report the role and effects of therapy with adrenomedullin as a novel,

Adrenomedullin (ADM) is a peptide that was discovered by the assay-based monitoring of platelet cAMP activity (Kitamura et al., 1993). This protein shows not only marked vasodilatory but also *in vivo* and *in vitro* anti-inflammatory activities (Isumi et al., 1998). To determine the efficacy of ADM in patients with RA, we researched the plasma level of ADM and its correlation with the plasma CRP level. The result showed that the plasma ADM level in patients with RA was twice that in healthy controls and strongly correlated with the blood CRP level, and the ADM level in synovial tissue in patients with RA was 3 times that in patients with osteoarthritis (Chosa et al., 2003). Then, thorough research is needed to examine whether the cultured RA synoviocytes are related to the ADM *in vitro*. The result showed that ADM was produced from RA synoviocytes and reduced the IL-6 level in cultured media (Fig. 5). These results suggest the close involvement of ADM in arthritis in RA. Therefore, to examine the therapeutic efficacy of intra-articular ADM injection, we injected ADM into the joint of a rabbit model of adjuvant arthritis, and confirmed the inhibition of arthritis at an early stage. These findings suggest the potentiality of ADM as a novel drug for the treatment of arthritis in RA (Okura et al.,

For measurement of plasma ADM, the study population consisted of 26 patients with RA aged 58–73 years (mean ± SD 62 ± 4 yrs), 10 with osteoarthritis (OA) aged 59–76 years

**2. Measured adrenomedullin (ADM) in patients with RA** 

**1. Introduction** 

2008).

**2.1 Patient background** 

promising targeted therapy.

Etsuo Chosa, Hiroaki Hamada and Toshiyuki Ohkura

*Mortor Organs, Faculty of Medicine, University of Miyazaki* 

**Rheumatoid Arthritis** 

Zagon, I.S., Wu, Y., McLaughlin, P.J. (1997). Opioid growth factor is present in human and mouse gastrointestinal tract and inhibits DNA synthesis. *Am J Physiol* 272 (4Pt 2): 1094-1104
